 | Up a level |
2020
Guery, Benoit, Georgopali, Areti, Karas, Andreas, Kazeem, Gbenga, Michon, Ingrid, Wilcox, Mark H. and Cornely, Oliver A. (2020). Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. J. Antimicrob. Chemother., 75 (4). S. 1014 - 1019. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2091
2019
Cornely, Oliver A., Vehreschild, Maria J. G. T., Adomakoh, Nicholas, Georgopali, Areti, Karas, Andreas, Kazeem, Gbenga and Guery, Benoit (2019). Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. Eur. J. Clin. Microbiol. Infect. Dis., 38 (6). S. 1187 - 1195. NEW YORK: SPRINGER. ISSN 1435-4373
Wilcox, Mark H., Cornely, Oliver A., Guery, Benoit, Longshaw, Chris, Georgopali, Areti, Karas, Andreas, Kazeem, Gbenga, Palacios-Fabrega, Jose Alejandro and Vehreschild, Maria J. G. T. (2019). Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study. Open Forum Infect. Dis., 6 (11). CARY: OXFORD UNIV PRESS INC. ISSN 2328-8957
2018
Guery, Benoit, Menichetti, Francesco, Anttila, Veli-Jukka, Adomakoh, Nicholas, Aguado, Jose Maria, Bisnauthsing, Karen, Georgopali, Areti, Goldenberg, Simon D., Karas, Andreas, Kazeem, Gbenga, Longshaw, Chris, Alejandro Palacios-Fabrega, Jose, Cornely, Oliver A. and Vehreschild, Maria J. G. T. (2018). Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect. Dis., 18 (3). S. 296 - 308. OXFORD: ELSEVIER SCI LTD. ISSN 1474-4457
Vehreschild, Maria J. G. T., Taori, Surabhi 
ORCID: 0000-0002-2976-4106, Goldenberg, Simon D., Thalhammer, Florian, Bouza, Emilio ORCID: 0000-0001-6967-9267, van Oene, Joop, Wetherill, Graham and Georgopali, Areti
(2018).
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
Eur. J. Clin. Microbiol. Infect. Dis., 37 (11).
S. 2097 - 2107.
NEW YORK:
SPRINGER.
ISSN 1435-4373